盐酸埃克替尼治疗体力状况较差EGFR基因状态不明肺腺癌的临床疗效

Clinical effects of icotinib on lung denocarcinoma patients with unknown EGFR gene status and poor performance status

目的评价埃克替尼治疗EGFR基因状态不明体力状况较差晚期肺腺癌患者的疗效及安全性。方法分析2012年8月至2014年8月在重庆市肿瘤研究所就诊的27例美国东部肿瘤协作组一体力状况（ECOG-PS）评分大于或等于2分的晚期EGFR基因状态不明肺腺癌患者，口服盐酸埃克替尼125mg，3次／d，评价近期疗效和不良反应，计算生存率。结果27例患者，客观缓解率（ORR）为29．6％，疾病控制率（DCR）为81．5％，中位无进展生存期（PFS）6个月。ECOG-PS评分得到改善的比例为70．4％，治疗前、后比较差异有统计学意义（Z=-2．157，P=0．031）。毒性反应主要为Ⅰ～Ⅱ度的皮疹、乏力、纳差及腹泻。结论埃克替尼治疗ECOG-PS≥2分、EGFR基因状态不明的晚期肺腺癌患者，不良反应未明显增加，耐受性良好，患者可以从埃克替尼的治疗中明显获益。

Objective This research is aimed to investigate the efficacy and toxicity of ieotinib for lung adenocareinoma patients with poor performance status and unknown EGFR gene status. Methods A total of 27 lung adenoeareinom patients with poor Eastern Cooperative Ontology Group-Performance status（ECOG-PS） and unknown EGFR gene status referred to Chongqing Caneer Institute from August 2012 to August 2014 were analyzed. Icotinih （125 rag） was orally administered three times per day. Asess the efficacy and adverse reaction,calculate survival rates. Results Among the 27 patients, the objective response rate（ORR） and disease control rates（DCR） were 29.6% and 81.5%, respectively. The median progression free survival time was 6.0 months. A total of 70.4% of patients had an significant improvment in ECOG-PS scores, following icotinib treatment （Z=- 2. 157, P= 0. 031）. Fatigue,anorexia and diarrhea were the most frequent adverse reaction,which defined as grade 1 to 2 rashes. Conclusion Lung adenocareinoma patients with poor performance status and unknown EGFR gene status may benefit from icotinib therapy,and patients were tolerated well.